Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Maze Therapeutics
Alloy raises $75m in venture funding to further its mission of open-source antibody technology discovery. It also spins out portfolio companies, like ophthalmic-focused Broadwing.
Newly public Aligos will team with Merck & Co. on oligonucleotide therapies for NASH. Maze Therapeutics launches ophthalmology and CV-focused spinouts with Alloy and BridgeBio.
The Dutch biotech's C-suite tells Scrip that the technology it has developed and now licensed to Genentech allows it to systematically go through the whole genome gene by gene and discover what the modifier of a particular disease is.
Previewing the year to come, our journalists contacted more than 80 industry executives and experts for their views on what 2020 could hold for the biopharma sector. A series of articles based on these discussions were published by In Vivo’s sister publication Scrip. The following are highlights of the key issues that are top of mind for industry leaders this year, including digital tools, advanced therapies, the US election and manufacturing.
- Gene Therapy, Cell Therapy
Drug Discovery Tools